Denosumab Approval Is “Highly Likely,”– Interview With Amgen’s Perlmutter
Executive Summary
In a Jan. 26 interview, Amgen Executive VP for Research and Development Roger Perlmutter talks about denosumab, follow-on biologics and how Amgen is avoiding the size-related innovation drought that many big pharma companies now face.
You may also be interested in...
Final Development Stage For Prolia Reflects Amgen's Eye On Advertising
Amgen's latest round of studies for the osteoporosis drug Prolia (denosumab) reflects the closing stage of the development program and shows how the company is laying groundwork for an advertising campaign - or at least a convincing argument for insurance coverage
Final Development Stage For Prolia Reflects Amgen's Eye On Advertising
Amgen's latest round of studies for the osteoporosis drug Prolia (denosumab) reflects the closing stage of the development program and shows how the company is laying groundwork for an advertising campaign - or at least a convincing argument for insurance coverage
Final Development Stage For Prolia Reflects Amgen's Eye On Advertising
Biotech's roll-out of clinical data on the RANK ligand inhibitor no longer is studies that supported the initial application but studies focused on particular claims or comparative advantages that will improve Prolia's commercial outlook.